Biophage Pharma Inc. Announces Commercial Launch of Titanium Hypersensitivity Detection Test at Mini Symposium on the Effect of Toxic Metals and Nanoparticles on Human Health
Published: Dec 06, 2007
MONTREAL, Dec. 6 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma is very
pleased to announce today the commercial launch of a new test for the
detection of titanium hypersensitivity during a mini symposium held in
Montreal on the effect of toxic metals and nanoparticles on human health.
Co-hosted by Biophage Pharma and the MELISA(R) Foundation, this Mini Symposium
was presented by Professor Vera Stejskal, inventor of the MELISA(R)
technology. Invited guests were given a tour of Biophage ImmunotoxLabs and
were able to interact with its scientists.